Short-Term Heart Rate Variability Predicts Cardiotoxicity Induced By Intracoronary Injection of Doxorubicin
World Small Animal Veterinary Association World Congress Proceedings, 2003
Suwanakiet Sawangkoon1; Anusak Kijtawornrat1; Tomohiro Nakayama2; Robert L. Hamlin2
1 Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, Patumwan, Bangkok, Thailand; 2 Department of Veterinary Biosciences, Faculty of Veterinary Medicine, The Ohio State University

Objective

This study was conducted to determine if cardiotoxicity could be detected, before other clinical signs, by measures of heart rate variability.

Materials & Methods

Seven healthy beagle hounds were given intracoronary injections of doxorubicin at a dose of 0.75 mg/kg once a week for 4 weeks. 5-minute ECG's were recorded at baseline and at the ninth week, and heart rate variability was expressed in both time and frequency domains. Ventricular function was quantified using shortening fraction and systolic time intervals (PEP/ET) obtained from M-mode echocardiograms when dogs were mildly sedated with butorphanol.

Results

Animals received doxorubicin had significantly lower the standard deviation of RR intervals (SDNN) and the square root of the mean of the sum of the squares of differences between adjacent RR intervals (RMSSD) at the ninth week compared to the baseline. The fractional shortening decreased significantly (p<0.05) while PEP/ET ratio increased significantly (p<0.05). SDNN was correlated with fractional shortening (r = 0.76, P<0.05) and PEP/ET ratio(r = 0.75, P<0.05) at the ninth week.

Conclusion

The present study suggests that the total power expression of heart rate variability is useful for prediction of the cardiotoxicity produced by doxorubicin.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Suwanakiet Sawangkoon
Department of Physiology, Faculty of Veterinary Science
Chulalongkorn University
Patumwan, Bangkok, Thailand


MAIN : Cardiology/Pulmonary : Cardiotoxicity: Doxorubicin
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27